Renal Denervation in Patients With Heart Failure and Severe Left Ventricular Dysfunction.

NCT ID: NCT01870310

Last Updated: 2013-06-06

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: NA
• Total Enrollment: 50 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2012-06-30
• Study Completion Date: 2016-06-30

Brief Summary

It is a randomized prospective controlled study evaluating the effect of transcatheter renal denervation on the clinical status of patients with chronic heart failure and its safety procedures. The working hypothesis of the study is that by performing transcatheter renal denervation in patients with chronic heart failure and severe left ventricular systolic dysfunction there will a resultant reduction in the renal sympathetic activation which in turn will reduce the number of hospitalizations and deaths from heart failure.

Detailed Description

Chronic heart failure in the European countries occurs in 2-3% of the population with a significant increase in the higher age groups (1). Improved treatment of acute conditions (especially myocardial infarction) has resulted in more patients entering into the category of chronic heart failure. Chronic heart failure has a poor prognosis. Diagnosis and treatment are challenging both medically and economically. Half of the patients with systolic heart failure die within 4 years and more than 50% of patients with severe heart failure (NYHA functional class of IV) die within one year (1). The current treatments for heart failure are not only aimed at influencing the symptoms, but also preventing the progression of heart failure to reduce mortality.

Heart failure leads to the activation of compensatory mechanisms designed to restore adequate cardiac output. These mechanisms are initially beneficial, but their long-term activation leads to further progression of the pathological process and deterioration of cardiac function. One of the basic pathophysiological processes in heart failure is excessive activation of the sympathetic nervous system. This causes increased levels of circulating catecholamines which is proportional to the severity of the disease that is patients with the highest levels of norepinephrine have the worst prognosis. Beta-blocker therapy which is designed to inhibit activity of sympathetic nervous system causes milder symptoms of heart failure in patients by modifying disturbed hemodynamics and ultimately the clinical status. In recent years, the therapeutic efficacy of beta-blockers in chronic heart failure has been verified in a number of controlled clinical trials (2-5). These studies have confirmed that long-term treatment with beta-blocker therapy alleviates the symptoms of heart failure, improves the clinical condition of the patients and reduces mortality like ACE inhibitors.

High activity of renal sympathetic nerves in patients with chronic heart failure is an early predictor of increased mortality (6). The main pathophysiological basis of this finding is probably excessive sodium retention due to direct activation of sympathetic fibers innervating renal tubules (7). Recent experimental work on animals have shown that surgical renal denervation inhibits an increase in renal vascular resistance, prevents a decrease in renal blood flow (8), and also prevents changes in expression of angiotensin receptors in the kidney (8).

Surgical sympathectomy began to be used for the treatment of severe and malignant hypertension more than 50 years ago. But this was a rather complicated procedure, which was accompanied by a number of adverse effects (orthostatic hypotension and tachycardia, shortness of breath, bowel and sexual disorders]. Moreover it required a long hospitalization of 2-4 weeks and then required a recovery period of 1-2 months. However this intervention led to a rapid decrease in pressure and a higher survival rate after surgery in a large observational study(9).

In recent years a method has been developed in which destruction of renal sympathetic nerves that are present in the adventitia of renal arterial walls is done by catheterization (10). This procedure uses a catheter with a radiofrequency ablator at its tip (Symplicity, Ardian / Medtronic, USA), which is introduced through the femoral artery and then progressively introduced into the renal arteries. A randomized study has demonstrated that this procedure has a high degree of safety for the patients and a high rate of efficacy as well. In patients with resistant hypertension treated with transcatheter renal denervation there was a significant drop in blood pressure of 33/11 mmHg (p < 0.0001) that occurred after 6 months compared to a control group receiving unmodified pharmacological treatment (11).

Conditions

Heart Failure

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Standard medical therapy

Group Type: NO_INTERVENTION

No interventions assigned to this group

Renal denervation + standard medical therapy

Patients in this arm will undergo catheterised renal denervation in addition to having optimization of medical therapy for heart failure.

Group Type: EXPERIMENTAL

Catheterised renal denervation

Intervention Type: PROCEDURE

Interventions

Catheterised renal denervation

Intervention Type: PROCEDURE

Other Intervention Names

Symplicity, Ardian / Medtronic, USA

Eligibility Criteria

Inclusion Criteria

• Patients over 18 years of age with chronic heart failure, ischemic and non-ischemic etiology.
• NYHA (New York Heart Association) class II-IV.
• LVEF (Left Ventricular Ejection Fraction) ≤ 35%.
• Patients treated with maximum tolerated doses of standard pharmacotherapy for heart failure, who were stable for at least four weeks without acute decompensated heart failure.
• Prior to enrollment, patients must give informed consent.

Exclusion Criteria

• Patients with history of acute coronary syndrome or stroke within the last 6 months.
• Significant valvular defects and/or planned cardiac surgery.
• Systolic blood pressure <110 mmHg.
• Advanced renal insufficiency (estimated GFR (Glomerular Filtration Rate) according to MDRD <30 ml/min/1.73 square meters).
• Unsuitable anatomy of renal arteries (presence of significant renal stenosis, renal artery narrower than 4 mm).
• Patients who underwent renal angioplasty or stent placement into the renal artery in the past.
• Severe coagulation disorders.
• Pregnancy or lactation.
• Refusal of the patient.
• Other diseases limiting prognosis of the patient to less than 2 years.
• Other reasons which in the opinion of the attending physician would preclude the individual from participating in the study.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University Hospital Olomouc

OTHER

Sponsor Role: lead

Responsible Party

doc. MUDr. Miloš Táborský, CSc., FESC, MBA

Head of Department of First Clinic of Internal Medicine - Cardiology

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Miloš Táborský, doc., MUDr., CSc., FESC, MBA

Role: PRINCIPAL_INVESTIGATOR

Head of Department of First Clinic of Internal Medicine - Cardiology, University Hospital, Olomouc.

Locations

University Hospital, Olomouc

Olomouc, Olomouc, Czechia

Site Status: RECRUITING

Countries

Czechia

Central Contacts

Dagmar Strnkova, Mgr.

Role: CONTACT

dagmarstrnkova@seznam.cz

+420 588 443 716

Albert Louis, MUDr.

Role: CONTACT

albertlouis3@gmail.com

+420 588 443 238

Facility Contacts

Miloš Táborský, doc., MUDr., CSc., FESC, MBA

Role: primary

milos.taborsky@fnol.cz

+420 588 443 201

Albert Louis, MUDr.

Role: backup

albertlouis3@gmail.com

+420 588 443 238

References

Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Stromberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K; ESC Committee for Practice Guidelines (CPG). ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J. 2008 Oct;29(19):2388-442. doi: 10.1093/eurheartj/ehn309. Epub 2008 Sep 17. No abstract available.

Reference Type: BACKGROUND

PMID: 18799522 (View on PubMed)

Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996 May 23;334(21):1349-55. doi: 10.1056/NEJM199605233342101.

Reference Type: BACKGROUND

PMID: 8614419 (View on PubMed)

Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999 Jun 12;353(9169):2001-7.

Reference Type: BACKGROUND

PMID: 10376614 (View on PubMed)

The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999 Jan 2;353(9146):9-13.

Reference Type: BACKGROUND

PMID: 10023943 (View on PubMed)

van Veldhuisen DJ, Cohen-Solal A, Bohm M, Anker SD, Babalis D, Roughton M, Coats AJ, Poole-Wilson PA, Flather MD; SENIORS Investigators. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). J Am Coll Cardiol. 2009 Jun 9;53(23):2150-8. doi: 10.1016/j.jacc.2009.02.046.

Reference Type: BACKGROUND

PMID: 19497441 (View on PubMed)

Petersson M, Friberg P, Eisenhofer G, Lambert G, Rundqvist B. Long-term outcome in relation to renal sympathetic activity in patients with chronic heart failure. Eur Heart J. 2005 May;26(9):906-13. doi: 10.1093/eurheartj/ehi184. Epub 2005 Mar 10.

Reference Type: BACKGROUND

PMID: 15764611 (View on PubMed)

DiBona GF, Kopp UC. Neural control of renal function. Physiol Rev. 1997 Jan;77(1):75-197. doi: 10.1152/physrev.1997.77.1.75.

Reference Type: BACKGROUND

PMID: 9016301 (View on PubMed)

Clayton SC, Haack KK, Zucker IH. Renal denervation modulates angiotensin receptor expression in the renal cortex of rabbits with chronic heart failure. Am J Physiol Renal Physiol. 2011 Jan;300(1):F31-9. doi: 10.1152/ajprenal.00088.2010. Epub 2010 Oct 20.

Reference Type: BACKGROUND

PMID: 20962112 (View on PubMed)

SMITHWICK RH. Hypertensive vascular disease; results of and indications for splanchnicectomy. J Chronic Dis. 1955 May;1(5):477-96. doi: 10.1016/0021-9681(55)90061-8. No abstract available.

Reference Type: BACKGROUND

PMID: 14367447 (View on PubMed)

Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, Kapelak B, Walton A, Sievert H, Thambar S, Abraham WT, Esler M. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009 Apr 11;373(9671):1275-81. doi: 10.1016/S0140-6736(09)60566-3. Epub 2009 Mar 28.

Reference Type: BACKGROUND

PMID: 19332353 (View on PubMed)

Symplicity HTN-2 Investigators; Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Bohm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet. 2010 Dec 4;376(9756):1903-9. doi: 10.1016/S0140-6736(10)62039-9. Epub 2010 Nov 17.

Reference Type: BACKGROUND

PMID: 21093036 (View on PubMed)

Other Identifiers

OLOMOUC 1

Identifier Type: -

Identifier Source: org_study_id